Research statistics

Setmelanotide research: publications and trials

What has been published on Setmelanotide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Setmelanotide works or is safe. For what it is and what the studies found, see the Setmelanotide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

129

Since 2009

Publications in 2026 so far

30

Through November 15, 2026

Human clinical research

35.7%

46 of 129 classified

Registered clinical trials

26

ClinicalTrials.gov

Randomized controlled trials

5

Publications reporting an RCT in people

Systematic reviews and meta-analyses

2

Preclinical studies

24.0%

19 animal · 9 in vitro · 3 computational

Records that only mention it

87

Not counted above

Status in the library: FDA-approved. Groups: Melanocortin agonists.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Setmelanotide publications by year and evidence

2009, Preclinical (animal, in vitro, computational): 1 of 12012, Preclinical (animal, in vitro, computational): 1 of 12015, Human clinical research: 1 of 22015, Preclinical (animal, in vitro, computational): 1 of 22016, Human clinical research: 1 of 32016, Preclinical (animal, in vitro, computational): 1 of 32016, Reviews and meta-analyses: 1 of 32017, Human clinical research: 1 of 12018, Human clinical research: 2 of 42018, Preclinical (animal, in vitro, computational): 1 of 42018, Reviews and meta-analyses: 1 of 42019, Preclinical (animal, in vitro, computational): 1 of 32019, Reviews and meta-analyses: 2 of 32020, Human clinical research: 4 of 72020, Reviews and meta-analyses: 2 of 72020, Other and not yet classified: 1 of 72021, Human clinical research: 2 of 152021, Preclinical (animal, in vitro, computational): 6 of 152021, Reviews and meta-analyses: 6 of 152021, Other and not yet classified: 1 of 152022, Human clinical research: 4 of 122022, Preclinical (animal, in vitro, computational): 3 of 122022, Reviews and meta-analyses: 4 of 122022, Other and not yet classified: 1 of 122023, Human clinical research: 4 of 162023, Preclinical (animal, in vitro, computational): 2 of 162023, Reviews and meta-analyses: 10 of 162024, Human clinical research: 6 of 202024, Preclinical (animal, in vitro, computational): 4 of 202024, Reviews and meta-analyses: 8 of 202024, Other and not yet classified: 2 of 202025, Human clinical research: 7 of 142025, Preclinical (animal, in vitro, computational): 2 of 142025, Reviews and meta-analyses: 4 of 142025, Other and not yet classified: 1 of 142026 (to date), Human clinical research: 14 of 302026 (to date), Preclinical (animal, in vitro, computational): 8 of 302026 (to date), Reviews and meta-analyses: 4 of 302026 (to date), Other and not yet classified: 4 of 30Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified010203020092016201920222026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
200901001
201201001
201511002
201611103
201710001
201821104
201901203
202040217
2021266115
2022434112
20234210016
2024648220
2025724114
2026 (to date)1484430

Study types

Review40
Animal study19
Other clinical trial17
Case report16
In vitro study9
Editorial, letter or other9
Observational human study8
Randomized controlled trial5
Computational study3
Guideline or consensus1
Meta-analysis1
Systematic review1

Research areas

From MeSH major topics. A paper can be in several areas.

Obesity and weight management95
Metabolic health35
Neurological and mental health35
Endocrinology22
Dermatology5
Cardiovascular4
Immune system4
Antimicrobial and infectious disease2
Cognitive health2
Oncology2
Gastrointestinal1
Longevity and aging1

Registered clinical trials

3 of 17 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 19 · Active, not recruiting: 2 · Recruiting: 2 · Approved for marketing: 1 · Enrolling by invitation: 1 · Unknown status: 1
Phase not applicable: 1 · Phase 1: 3 · Phase 1 / Phase 2: 1 · Phase 2: 9 · Phase 2 / Phase 3: 1 · Phase 3: 9 · Phase 4: 2

TrialStatusPhaseStartedResults
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)NCT07496463 · 1 enrolledEnrolling by invitationPhase 22026-07—
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)NCT06760546 · 39 enrolledRecruitingPhase 32025-09—
A Study of Setmelanotide in Patients With Prader-Willi SyndromeNCT06772597 · 18 enrolledActive, not recruitingPhase 22025-03—
Open-Label Extension Study of SetmelanotideNCT06596135 · 28 enrolledCompletedPhase 32024-10—
A Trial of Setmelanotide in Acquired Hypothalamic ObesityNCT05774756 · 143 enrolledActive, not recruitingPhase 32023-04Posted
Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic ObesityNCT07674290 · 200 enrolledRecruitingPhase 42023-01—
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayNCT05093634 · 296 enrolledCompletedPhase 32022-04Posted
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityNCT04966741 · 12 enrolledCompletedPhase 32022-03Posted
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayNCT05194124 · 19 enrolledCompletedPhase 32021-12Posted
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayNCT04963231 · 164 enrolledCompletedPhase 22021-11Posted
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy ParticipantsNCT05046132 · 77 enrolledCompletedPhase 42021-08Posted
Open-Label Study of Setmelanotide in Hypothalamic ObesityNCT04725240 · 18 enrolledCompletedPhase 22021-06Posted
A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal ImpairmentNCT04348175 · 32 enrolledCompletedPhase 12020-07—
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityNCT03746522 · 52 enrolledCompletedPhase 32018-11Posted
Long Term Extension Trial of SetmelanotideNCT03651765 · 205 enrolledCompletedPhase 2, Phase 32018-07Posted
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency ObesityNCT03287960 · 15 enrolledCompletedPhase 32018-01Posted
Setmelanotide in a Single Patient With Partial LipodystrophyNCT03262610 · 1 enrolledCompletedPhase 22017-08—
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityNCT02896192 · 15 enrolledCompletedPhase 32017-02Posted
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityNCT03013543 · 213 enrolledCompletedPhase 22017-02Posted
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeNCT02311673 · 40 enrolledCompletedPhase 22015-03Posted
RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient PatientsNCT02507492 · 10 enrolledUnknown statusPhase 22015-01—
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese PatientsNCT02041195 · 99 enrolledCompletedPhase 1, Phase 22014-01Posted
Effects of RM-493 on Energy Expenditure in Obese IndividualsNCT01867437 · 15 enrolledCompletedPhase 12013-05—
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsNCT01749137 · 74 enrolledCompletedPhase 22013-01Posted
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic VolunteersNCT02431442 · 57 enrolledCompletedPhase 12012-01—
An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)NCT05183802Approved for marketingPhase not applicable——

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis.

    Expert opinion on drug safety · February 12, 2025 · Meta-analysis · cited 3 times

    PMID 39924461 · DOI 10.1080/14740338.2025.2465880 · Reviews and meta-analyses

  2. A systematic literature review of economic evaluations of setmelanotide.

    European journal of clinical pharmacology · April 20, 2026 · Systematic review · cited 0 times

    PMID 42008191 · DOI 10.1007/s00228-026-04058-y · Reviews and meta-analyses

  3. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.

    The New England journal of medicine · July 1, 2026 · Randomized controlled trial · cited 12 times · open access

    PMID 42418774 · DOI 10.1056/nejmoa2512275 · Human clinical research

  4. Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome.

    The Journal of clinical endocrinology and metabolism · September 1, 2025 · Randomized controlled trial · cited 11 times · open access

    PMID 39919037 · DOI 10.1210/clinem/dgaf079 · Human clinical research

  5. Could setmelanotide be the game-changer for acquired hypothalamic obesity?

    Frontiers in endocrinology · January 4, 2024 · Randomized controlled trial · cited 22 times · open access

    PMID 38239988 · DOI 10.3389/fendo.2023.1307889 · Human clinical research

  6. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.

    The lancet. Diabetes & endocrinology · November 7, 2022 · Randomized controlled trial · cited 205 times · open access

    PMID 36356613 · DOI 10.1016/s2213-8587(22)00277-7 · Human clinical research

  7. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals.

    The Journal of clinical endocrinology and metabolism · February 12, 2015 · Randomized controlled trial · cited 174 times · open access

    PMID 25675384 · DOI 10.1210/jc.2014-4024 · Human clinical research

  8. Impact of setmelanotide on metabolic syndrome risk in patients with proopiomelanocortin or leptin receptor deficiencies.

    The Journal of clinical endocrinology and metabolism · October 19, 2026 · Other clinical trial · cited 0 times

    PMID 42895739 · DOI 10.1210/clinem/dgag345 · Human clinical research

  9. Quality of life improvements with setmelanotide treatment in acquired hypothalamic obesity: TRANSCEND trial interview results from US participants.

    Frontiers in behavioral neuroscience · July 15, 2026 · Other clinical trial · cited 0 times · open access

    PMID 42528856 · DOI 10.3389/fnbeh.2026.1830070 · Human clinical research

  10. Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.

    Obesity (Silver Spring, Md.) · February 17, 2026 · Other clinical trial · cited 2 times · open access

    PMID 41703984 · DOI 10.1002/oby.70125 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.

    The lancet. Diabetes & endocrinology · October 30, 2020 · Other clinical trial · cited 487 times · open access

    PMID 33137293 · DOI 10.1016/s2213-8587(20)30364-8 · Human clinical research

  2. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

    The New England journal of medicine · July 1, 2016 · Other clinical trial · cited 482 times

    PMID 27468060 · DOI 10.1056/nejmoa1512693 · Human clinical research

  3. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.

    EClinicalMedicine · March 20, 2023 · Review · cited 457 times · open access

    PMID 36992862 · DOI 10.1016/j.eclinm.2023.101882 · Reviews and meta-analyses

  4. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.

    Nature medicine · May 7, 2018 · Other clinical trial · cited 309 times

    PMID 29736023 · DOI 10.1038/s41591-018-0015-9 · Human clinical research

  5. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.

    Molecular metabolism · July 8, 2017 · Other clinical trial · cited 302 times · open access

    PMID 29031731 · DOI 10.1016/j.molmet.2017.06.015 · Human clinical research

Latest publications

  1. Early nutrition impacts later setmelanotide treatment of obesity in mice.

    JCI insight · November 9, 2026 · Animal study · cited 0 times · open access

    PMID 43001579 · DOI 10.1172/jci.insight.197382 · Animal studies

  2. Impact of setmelanotide on metabolic syndrome risk in patients with proopiomelanocortin or leptin receptor deficiencies.

    The Journal of clinical endocrinology and metabolism · October 19, 2026 · Other clinical trial · cited 0 times

    PMID 42895739 · DOI 10.1210/clinem/dgag345 · Human clinical research

  3. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.

    The New England journal of medicine · October 1, 2026 · Editorial, letter or other · cited 0 times

    PMID 42874119 · DOI 10.1056/nejmc2610994 · Commentary and other

  4. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.

    The New England journal of medicine · October 1, 2026 · Editorial, letter or other · cited 0 times

    PMID 42874120 · DOI 10.1056/nejmc2610994 · Commentary and other

  5. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. Reply.

    The New England journal of medicine · October 1, 2026 · Editorial, letter or other · cited 0 times

    PMID 42874121 · DOI 10.1056/nejmc2610994 · Commentary and other

  6. Sequential Liraglutide and Setmelanotide Therapy in Bardet-Biedl Syndrome: Metabolic and Renal Outcomes in a Real-World Case Report and Literature Review.

    Nephron · September 15, 2026 · Case report · cited 0 times

    PMID 42743093 · DOI 10.1159/nef/adtag006 · Human clinical research

  7. Setmelanotide Response Variability in Two Genetically Confirmed Pediatric Kidney Transplant Recipients with Bardet-Biedl Syndrome.

    International journal of molecular sciences · August 29, 2026 · Case report · cited 1 times · open access

    PMID 42737637 · DOI 10.3390/ijms27177740 · Human clinical research

  8. Setmelanotide

    August 15, 2026 · Review · cited 0 times · open access

    PMID 42672527 · Reviews and meta-analyses

  9. Discovery of TL10: A Soluble and Long-Acting MC4R Agonist with Tunable Lipidation for Sustained Pharmacological Activity.

    Journal of medicinal chemistry · August 1, 2026 · Animal study · cited 0 times

    PMID 42611594 · DOI 10.1021/acs.jmedchem.6c01457 · Animal studies

  10. Melanocortin-4 Receptor Regulation of Endocrine Axes and Clinical Effects of Setmelanotide.

    The Journal of clinical endocrinology and metabolism · August 1, 2026 · Observational human study · cited 1 times · open access

    PMID 42538728 · DOI 10.1210/clinem/dgag293 · Human clinical research

Browse all 129 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Imcivree; RM-493; Setmelanotida; Setmelanotide; Setmelanotidum

((TITLE_ABS:"Imcivree" OR CHEM:"Imcivree") OR (TITLE_ABS:"RM-493" OR CHEM:"RM-493" OR TITLE_ABS:"RM493" OR CHEM:"RM493") OR (TITLE_ABS:"Setmelanotida" OR CHEM:"Setmelanotida") OR (TITLE_ABS:"Setmelanotide" OR CHEM:"Setmelanotide") OR (TITLE_ABS:"Setmelanotidum" OR CHEM:"Setmelanotidum")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Setmelanotide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/setmelanotide